Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov-Dec;43(6):1021-1032.
doi: 10.1590/S1677-5538.IBJU.2016.0510.

Prostate cancer in renal transplant recipients

Affiliations
Review

Prostate cancer in renal transplant recipients

Benjamin A Sherer et al. Int Braz J Urol. 2017 Nov-Dec.

Abstract

As patients with end-stage renal disease are receiving renal allografts at older ages, the number of male renal transplant recipients (RTRs) being diagnosed with prostate cancer (CaP) is increasing. Historically, the literature regarding the management of CaP in RTR's is limited to case reports and small case series. To date, there are no standardized guidelines for screening or management of CaP in these complex patients. To better understand the unique characteristics of CaP in the renal transplant population, we performed a literature review of PubMed, without date limitations, using a combination of search terms including prostate cancer, end stage renal disease, renal transplantation, prostate cancer screening, prostate specific antigen kinetics, immunosuppression, prostatectomy, and radiation therapy. Of special note, teams facilitating the care of these complex patients must carefully and meticulously consider the altered anatomy for surgical and radiotherapeutic planning. Active surveillance, though gaining popularity in the general low risk prostate cancer population, needs further study in this group, as does the management of advance disease. This review provides a comprehensive and contemporary understanding of the incidence, screening measures, risk stratification, and treatment options for CaP in RTRs.

Keywords: Kidney Transplantation; Prostate-Specific Antigen; Prostatectomy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. The Organ Procurement and Transplant Network. [Accessed June 18, 2014]. Available at. < https://optn.transplant.hrsa.gov/>.
    1. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of câncer after solid organ transplantation. Cancer. 2013;119:2300–2308. - PMC - PubMed
    1. Penn I. Posttransplant malignancies. Transplant Proc. 1999;31:1260–1262. - PubMed
    1. Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant Sci. 1994;4:23–32. - PubMed
    1. U.S. Renal Data System . USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2003. [Accessed June 18, 2014]. Available at. < https://www.usrds.org/2014/view/>.

Substances